STOCK TITAN

ViewRay Inc. - VRAY STOCK NEWS

Welcome to our dedicated news page for ViewRay (Ticker: VRAY), a resource for investors and traders seeking the latest updates and insights on ViewRay.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ViewRay's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ViewRay's position in the market.

News
Rhea-AI Summary
NUBURU, Inc. has announced the appointment of Brian Knaley as the new Chief Executive Officer, replacing Dr. Mark Zediker. Knaley, who previously served as the Company's Chief Financial Officer, brings over 25 years of experience in finance and operations. The Board is confident that Knaley's expertise will support the Company's transformation and drive its next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.8%
Tags
management
-
News
Rhea-AI Summary
NUBURU, Inc. has announced the appointment of Brian Knaley as the new Chief Executive Officer, replacing Dr. Mark Zediker. Knaley, who previously served as the Company's Chief Financial Officer, brings over 25 years of experience in finance and operations. The Board is confident that Knaley's expertise will support the Company's transformation and drive its next phase of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
management
-
Rhea-AI Summary
ViewRay, Inc. (Nasdaq: VRAY) has received a letter from Nasdaq stating that its securities will be delisted due to the company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code and concerns about its ability to meet the minimum bid price requirement. Trading of the company's stock will be suspended on July 26, 2023, and it is expected to begin trading on the OTC markets under the symbol 'VRAYQ'. The transition to the OTC markets will not affect the company's operations in chapter 11.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
ViewRay, Inc. has filed for Chapter 11 bankruptcy and plans to sell its business. The company has secured $6 million in debtor-in-possession financing to support ongoing operations. The CEO and two board members have resigned, and new appointments have been made.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-81.17%
Tags
none
-
Rhea-AI Summary
ViewRay, Inc. announced that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.8%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.19%
Tags
earnings
-
Rhea-AI Summary
ViewRay, Inc. (NASDAQ: VRAY) announces details for the release of Q1 2023 financial results and conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.01%
Tags
earnings
-
Rhea-AI Summary
ViewRay, Inc. announces preliminary financial results for Q1 2023. Received 13 new orders for MRIdian systems totaling $68 million. Total backlog increased to $411 million. Total revenue for Q1 2023 was $23 million. Net loss for Q1 2023 was $29 million. Adjusted EBITDA was a loss of $25 million. Company's Board of Directors retained Goldman Sachs as financial advisor to evaluate strategic alternatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.2%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.2%
Tags
earnings
ViewRay Inc.

NYSE:VRAY

VRAY Rankings

VRAY Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Oakwood Village

About VRAY

mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving